Health Care • Misc Health and Biotechnology Services
$85.94 ▼ -5.06
(-5.56%)
MKT CAP: $1.44B • VOL: 138.6K
52W L $7 52W H $133
AGL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.93B | $6.06B | $4.32B |
| YoY Revenue Growth % | -2.1% | +40.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$463.2M | -$292.1M | -$232.1M |
| Operating Margin % | -7.8% | -4.8% | -5.4% |
| Net Income (GAAP) | -$391.3M | -$260.2M | -$262.6M |
| EBITDA (Normalized) | -$452.6M | -$281.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$105.8M | -$57.8M | -$156.2M |
| Capital Expenditures (CapEx) | $13.2M | $13.3M | — |
| Free Cash Flow (FCF) | -$119.0M | -$71.0M | -$156.2M |
| FCF Margin % | -2.0% | -1.2% | -3.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $173.7M | $188.2M | — |
| Total Debt (Short + Long Term) | $15.8M | $34.9M | — |
| Total Stockholders' Equity | $126.7M | $471.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AGL.